Professor Francesco Rubino
Chair of Metabolic and Bariatric Surgery
Research interests
- Diabetes
Biography
Professor Rubino’s research showed that the anti-diabetes effect of certain bariatric procedures, particularly gastric bypass surgery, results from mechanisms beyond weight loss. This evidence provided a scientific rationale for surgical treatment of type 2 diabetes, including that of less obese patients. Professor Rubino’s research-finding and theories also point to a role of the gastrointestinal tract in the pathophysiology of diabetes and obesity. His clinical expertise includes laparoscopic, bariatric, metabolic and upper digestive surgery, including gastric bypass, sleeve gastrectomy, gastric banding and novel procedures. He is internationally recognized as one of the world’s leaders in the research, teaching and practice of metabolic and weight-loss surgery.
Professor Rubino received his MD and completed his residency in general surgery at the Catholic University / Policlinico Gemelli in Rome, Italy. He completed fellowships in laparoscopic surgery at the European Institute of Telesurgery in Strasbourg, France; Mount Sinai Medical Center, New York; and Cleveland Clinic.
A member of many professional organizations, Professor Rubino is the recipient of numerous awards, has given hundreds of presentations throughout the world, and is the author of over 100 articles in peer-reviewed journals and book chapters. He was one of the co-organizers of the landmark Diabetes Surgery Summit in Rome in 2007, an influential scientific event where leading international authorities for the first time reached a consensus on the best candidates for the surgical treatment of diabetes. Professor Rubino also served as Congress Director and organized the 1st and 2nd World Congress on Interventional Therapies for Type 2 Diabetes in New York City, bringing together over 1,000 multidisciplinary diabetes experts from 62 countries.
For several consecutive years, Professor Rubino was selected by both US News & World Report and Castle Connolly as one of “America’s Top Doctors” and was selected by Crain’s NY Business as a notable “40 under 40”, which recognizes young rising stars in the healthcare, business, non-profit and entertainment industries.
His work has been featured in journals such as the New York Times, the Wall Street Journal, Newsweek, 60 Minutes on CBS, the Guardian, and the New Scientists as well as on national TVs and newspapers in Japan, Italy, Qatar, Brazil, South Africa and other countries.
Media Links
- Dr Rubino's print interview on Diabetic Surgery
- Pioneering Diabetes Surgery
- Diabetes Surgery-Fox News
- Interview on Diabetes Surgery with Dr. Francesco Rubin
- Dr. Rubino's Webcast on Surgical Treatment for diabetes type 2
- Crains Health article on Diabetes Surgery Clinical Trial
- Science Daily article about Diabetes Type 2 Clinical Trial
- Center for Advanced Digestive Care
- Wall Street Journal reports Dr. Rubino's diabetes surgery works better than medications
- New York Times article on Dr. Rubino's diabetes surgery
- ABC News story about Dr. Rubino's diabetes surgery
- NPR Story about Dr. Rubino's diabetes surgery
- HealthDay story about Dr. Rubino's diabetes surgery
- Huffington Post story on Dr. Rubino's diabetes surgery
- Daily News story on Dr. Rubino's diabetes surgery
- WCBS-TV story on Dr. Rubino's diabetes surgery
Research
A pledge to end the social stigma of obesity
People with obesity commonly face social stigma, including discrimination in the workplace as well as in educational and healthcare settings.
Project status: Ongoing
Obesity, Type 2 Diabetes & Immunometabolism Research Group
We are experimental medicine researchers and clinical academics. Our ‘bench to bedside’ research spans from basic discovery science, investigating the immune system and the susceptibility to obesity/insulin resistance, to an array of clinical studies investigating the impact of pharmacotherapy, bariatric surgery, diet and ethnicity on obesity and type 2 diabetes.
News
Surgery most effective treatment of metabolic liver disease
Metabolic (bariatric) surgery is more effective than medications and lifestyle interventions for the treatment of advanced non-alcoholic fatty liver disease.
Gastrointestinal surgery can be a cure for type 2 diabetes finds new long-term study
The results of a randomized clinical trial with the longest follow up to date show that metabolic surgery is more effective than medications and lifestyle...
COVID-19 may trigger new diabetes, experts warn
Emerging evidence suggests that COVID-19 may actually trigger the onset of diabetes in healthy people and also cause severe complications of pre-existing...
Delaying bariatric and metabolic surgery during Covid-19 pandemic puts patients at risk, experts warn
New guidance identifies patients with the greatest need for bariatric and metabolic surgery as experts warn delaying treatment could put them at a greater...
Scientific community pledges to end obesity stigma
Coinciding with World Obesity Day, over 100 medical and scientific organisations have today pledged their support for a consensus statement that recognises...
Research
A pledge to end the social stigma of obesity
People with obesity commonly face social stigma, including discrimination in the workplace as well as in educational and healthcare settings.
Project status: Ongoing
Obesity, Type 2 Diabetes & Immunometabolism Research Group
We are experimental medicine researchers and clinical academics. Our ‘bench to bedside’ research spans from basic discovery science, investigating the immune system and the susceptibility to obesity/insulin resistance, to an array of clinical studies investigating the impact of pharmacotherapy, bariatric surgery, diet and ethnicity on obesity and type 2 diabetes.
News
Surgery most effective treatment of metabolic liver disease
Metabolic (bariatric) surgery is more effective than medications and lifestyle interventions for the treatment of advanced non-alcoholic fatty liver disease.
Gastrointestinal surgery can be a cure for type 2 diabetes finds new long-term study
The results of a randomized clinical trial with the longest follow up to date show that metabolic surgery is more effective than medications and lifestyle...
COVID-19 may trigger new diabetes, experts warn
Emerging evidence suggests that COVID-19 may actually trigger the onset of diabetes in healthy people and also cause severe complications of pre-existing...
Delaying bariatric and metabolic surgery during Covid-19 pandemic puts patients at risk, experts warn
New guidance identifies patients with the greatest need for bariatric and metabolic surgery as experts warn delaying treatment could put them at a greater...
Scientific community pledges to end obesity stigma
Coinciding with World Obesity Day, over 100 medical and scientific organisations have today pledged their support for a consensus statement that recognises...